Taro Pharmaceutical price target lowered to $35 from $54 at H.C. Wainwright

H.C. Wainwright analyst Raghuram Selvaraju lowered the firm’s price target on Taro Pharmaceutical to $35 from $54 and keeps a Buy rating on the shares. The analyst cites continued weakness in Taro’s operating performance for the target drop. The firm now believes Taro may face a challenging operating environment for some time to come.